Sarilumab
Revision as of 21:05, 18 January 2022 by Rossdonaldson1 (talk | contribs)
Administration
- Type:
- Dosage Forms:
- Routes of Administration:
- Common Trade Names:
Adult Dosing
COVID
- Use the single-dose, prefilled syringe (not the prefilled pen) for SQ injection[1]
- Reconstitute sarilumab 400 mg in 100 cc 0.9% NaCl and administer as an IV infusion over 1 hour[2]
Pediatric Dosing
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
- Use as an alternative immunomodulatory drug if tocilizumab is not available or not feasible to use (BIIa).
- In the United States, the currently approved route of administration for sarilumab is SQ injection. In the REMAP-CAP trial, the SQ formulation was used to prepare the IV infusion.